Advertisement
Advertisement
U.S. Markets open in 1 hr 27 mins
Advertisement
Advertisement
Advertisement
Advertisement

Merus N.V. (MRUS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
28.30-0.23 (-0.81%)
At close: 4:00PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Merus to Participate in a Fireside Chat at the Jefferies London Healthcare Conference (Virtual)

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies London Healthcare Conference (Virtual). The prerecorded fireside chat will be available starting on Thursday, November 18, 2021 at 8:00 am

  • Simply Wall St.

    Could The Merus N.V. (NASDAQ:MRUS) Ownership Structure Tell Us Something Useful?

    If you want to know who really controls Merus N.V. ( NASDAQ:MRUS ), then you'll have to look at the makeup of its share...

  • GlobeNewswire

    Merus Announces Pricing of Public Offering of Common Shares

    UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the pricing of an underwritten public offering of 3,859,650 common shares, at a public offering price of $28.50 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purchase up

Advertisement
Advertisement